As the project Supporter, BLA congratulates Lantern Pharma on receiving IND may proceed letter for LP-184 project
Gaithersburg, MD (June 29, 2023) – BLA Regulatory, LLC, a full-service biopharma regulatory consultancy, congratulates Lantern Pharma on receiving US FDA IND may proceed letter to initiate its first-in-human Phase 1 clinical trial of LP-184, which is being developed for multiple advanced solid tumors and central nervous system (CNS) cancers [1].
About BLA Regulatory, LLC
BLA Regulatory, LLC, is a full-service drug regulatory consultancy focusing on the US with global reach to other major markets. BLA provides comprehensive regulatory strategy and operation services from pre-IND strategic planning, IND preparation & submission, all the way to submission and approval of BLA/NDA. Our goal is to help move your product through the development cycle efficiently. With credits of 300+ INDs and 50+ NDAs/BLAs to our senior consultants, BLA brings clients a broad range of experiences from Big Pharma, CROs, and the FDA. Our services expand across regulatory, CMC, nonclinical, clinical, biostatistics, scientific writing, project management, eCTD publishing, and submission. We have extensive experience across therapeutic areas such as oncology, respiratory, addiction, autoimmune, inflammatory, metabolic, and cardiovascular diseases.
For further information contact:
Reference
[1] Lantern Pharma “Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors” 12 June. 2023,
https://gsrs.ncats.nih.gov/ginas/app/beta/substances/L683VC69K8